Teva Respiratory Announces Positive Results From Phase III Trial of BDP HFA … – PR Newswire (press release)
July 29th, 2010 | 
Author: |
Teva Respiratory Announces Positive Results From Phase III Trial of BDP HFA …
PR Newswire (press release) The most common adverse events reported were nasal discomfort, headache, epistaxis (nosebleed), nausea and urticaria (hives). Allergic rhinitis (AR) is a … and more » |
Posted in 
Tags: